US › Healthcare

Edesa Biotech Inc (EDSA)

US · Healthcare · Biotechnology

$5.36+2.49%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$50,918
Net profit
$-4.2M
Profit YoY
-165.2%
EPS
$-0.49
EPS estimate
$-0.26
Net margin
-8,284.6%

EPS came in at -0.49 against a street estimate of -0.26 — a miss of 88.5%.

Key statistics

Market cap
$49.2M
Forward P/E
0.2
P/B
27.25
Book value
$0.20
EPS (TTM)
$-1.31
52-week high
$20.32
52-week low
$0.72
50-day MA
$6.89
200-day MA
$4.91
Beta
1.05

Analyst view

Analysts rate Edesa Biotech Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $16.33.

Shareholding

Insiders
18.66%
Institutions
39.08%

Largest institutional holders

FundStake
Velan Capital Investment Management LP8.59%
Rubric Capital Management LP7.14%
Perceptive Advisors LLC5.85%
Jane Street Group LLC1.20%
Vanguard Capital Management, LLC0.89%
Geode Capital Management, LLC0.80%
Vanguard Fiduciary Trust Co0.40%
State Street Corp0.39%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Edesa Biotech Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.